Exelixis Inc

Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company markets several key medications. Its product portfolio includes CABOMETYX tablets, prescribed for patients with advanced renal cell carcinoma who have previously undergone anti-angiogenic therapy, and COMETRIQ capsules, utilized in the management of progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are derived from cabozantinib, a potent inhibitor targeting multiple tyrosine kinases, notably MET, AXL, RET, and VEGF receptors. Additionally, Exelixis provides COTELLIC, an MEK inhibitor employed as part of a combination regimen for advanced melanoma. In Japan, it offers MINNEBRO, an oral, non-steroidal selective blocker of the mineralocorticoid receptor, indicated for the treatment of hypertension. Its development pipeline features several promising candidates. These include XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases implicated in cancer growth and dissemination; XB002, an antibody-drug conjugate comprising a human monoclonal antibody against tissue factor (TF), currently being evaluated for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for advanced or metastatic solid tumors. Exelixis maintains a wide array of research collaborations and licensing agreements with numerous partners, such as Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. The company, originally known as Exelixis Pharmaceuticals, Inc., adopted its current name, Exelixis, Inc., in February 2000. Established in 1994, its corporate headquarters are situated in Alameda, California.